CARs in the Lead Against Multiple Myeloma.
CARs in the Lead Against Multiple Myeloma.
复制标题
DOI：
10.1007/s11899-017-0373-2
复制
发表时间：
2017-04
影响因子：
2.9
通讯作者：
Maus MV
中科院分区：
文献类型：
--
作者：
Ormhøj M;Bedoya F;Frigault MJ;Maus MV
CD 19定向嵌合抗原受体（CAR）T细胞疗法在慢性和急性白血病中的最近临床成功已经导致将该技术扩展到其他血液恶性肿瘤和实体瘤的兴趣增加。现在，使用CAR T细胞技术正在取得进展，以靶向骨髓瘤抗原，如BCMA，CD 138和κ轻链以及推定的骨髓瘤干细胞上的CD 19。迄今为止，只有有限的多发性骨髓瘤患者接受了CAR-T细胞治疗，但初步结果令人鼓舞。在这篇综述中，我们总结了最近报道的利用CAR T细胞治疗MM的临床试验结果。
The recent clinical success of CD19 directed chimeric antigen receptor (CAR) T-cell therapy in chronic and acute leukemia has led to increased interest in broadening this technology to other hematological malignancies and solid tumors. Now, advances are being made using CAR T cell technology to target myeloma antigens such as BCMA, CD138 and kappa-light chain as well as CD19 on putative myeloma stem cells. To date, only a limited multiple myeloma patients have received CAR-T cell therapy but preliminary results have been encouraging. In this review, we summarize the recently reported results of clinical trials conducted utilizing CAR T-cell therapy in MM.